(800) 574 – 6320
Request a call back
-
Mentor Capital Cancer Immunotherapy Index Gains on Medicare Advisory Committee Approval of $93,000 Provenge Immunotherapy Treatment by Dendreon for Prostate Cancer
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports correlated gains across the 10 trading companies of the Mentor Capital Cancer Immunotherapy Index with the recent 6.6% one-day price appreciation of Index pioneer and market leader, Dendreon (NASDAQ:DNDN). The Dendreon price appreciation follows the Medicare Evidence Development &…
-
Mentor Capital Takes Investment Position in Each of 10 Cancer Immunotherapy Index Companies
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) has completed the set-up and initial funding of the Cancer Immunotherapy Index Fund. Through the CII Fund, Mentor Capital has now taken an initial equity position in each of the ten companies that make up Mentor Capital's proprietary Cancer Immunotherapy Index. The equally weighted CI Index was…
-
Mentor Capital Retains Network 1 Financial Securities for Comprehensive Investment Banking Services
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) today announced the engagement of Network 1 Financial Securities, Inc. to provide investment banking, investor relations and financial advisory services. Network 1 Financial Securities, Inc. is headquartered in Red Bank, New Jersey and is an independent full-service securities firm. …
-
Mentor Capital, Inc. Initiates Trading at $1.05/sh (P/E of 2.7x)
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets: MNTR) began trading under its new symbol MNTR, at an initial Asking price of $1.05 per share. The initial price calculates to a current P/E ratio of 2.7x on a diluted basis. The Company holds 99 cents per diluted share in cash, investment in securities, and notes or receivables from its investments. Mentor Capital, Inc.…